Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Filgotinib
Jyseleca
Routinely available
SMC (SMC2467)
25/05/2022
Indication
For treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
Therapeutic Area
Gastro-intestinal system
Status Description
Routinely available in line with national guidance
Formulation
100mg and 200mg film-coated tablets
Comments
May 2022 - Routinely available in line with national guidance. Included on the ERF for Specialist Use only.
Link to Advice
Advice Published
09/05/2022
SMC Submission Type
Abbreviated
SMC Status
Accepted